Pharmacokinetics of alvimopan, a novel, oral, peripherally acting muopioid receptor (PAM-OR) antagonist, and its primary metabolite in the elderly.

被引：0
|
作者：
Foss, J
Marbury, TC
Melikian, A
Schmith, V
Du, W
Wallin, B
机构：
[1] Adolor Corp, Exton, PA USA
[2] Orlando Clin Res Ctr, Orlando, FL USA
[3] Drug Dev Resources LLC, Mountain Lakes, NJ USA
[4] GlaxoSmithKline Inc, Philadelphia, PA USA
来源：
PHARMACOTHERAPY | 2005年 / 25卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1484 / 1484
页数：1
相关论文
共 9 条
  • [1] Pharmacokinetics and safety of alvimopan, a novel, oral, peripherally acting mu-opioid receptor (PAM-OR) antagonist, and in patients with renal impairment.
    Foss, J
    Marbury, TC
    Melikian, A
    Schmith, V
    Du, W
    Wallin, B
    PHARMACOTHERAPY, 2005, 25 (10): : 1483 - 1484
  • [2] Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist - A study in patients with chronic idiopathic constipation (CIC) not taking opioid medication
    Kelleher, Dennis
    Johanson, John
    Pobiner, Bonnie
    Carter, Eric
    Dukes, George
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S480 - S480
  • [3] Efficacy of alvimopan, a peripherally activing mu-opioid receptor (PAM-OR) antagonist, and timing of preoperative dosing: pharmacodynamic and pharmacokinetic consideration in patients undergoing open laparotomy.
    Kariv, Y
    Viscusi, E
    Wolff, B
    Delaney, C
    Senagore, A
    Du, W
    Techner, L
    Wallin, B
    PHARMACOTHERAPY, 2005, 25 (10): : 1484 - 1484
  • [4] Perioperative Administration of Alvimopan, a Novel Peripherally Acting Mu-opioid Receptor Antagonist, Is Associated with Improved Resource Utilization in Patients Undergoing Open Aortic Surgery
    Burruss, Matthew B.
    Ehlert, Bryan A.
    Capps, Timothy W.
    Bogey, William M.
    Parker, Frank M.
    Powell, Charles S.
    Stoner, Michael C.
    JOURNAL OF VASCULAR SURGERY, 2012, 55 (06) : 31 - 31
  • [5] Alvimopan:: An oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction -: A 21-day treatment-randomized clinical trial
    Paulson, DM
    Kennedy, DT
    Donovick, RA
    Carpenter, RL
    Cherubini, M
    Techner, L
    Du, W
    Ma, YJ
    Schmidt, WK
    Wallin, B
    Jackson, D
    JOURNAL OF PAIN, 2005, 6 (03): : 184 - 192
  • [6] Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain
    Webster, Lynn
    Jansen, Jan Peter
    Peppin, John
    Lasko, Ben
    Irving, Gordon
    Morlion, Bart
    Snidow, Jerry
    Pierce, Amy
    Mortensen, Eric
    Kleoudis, Christi
    Carter, Eric
    PAIN, 2008, 137 (02) : 428 - 440
  • [7] Pharmacokinetics, metabolite profiling, safety, and tolerability of inhalation aerosol of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, in healthy Chinese subjects
    Gao, Huaye
    Li, Jintong
    Chen, Xiaoping
    Sun, Zhanguo
    Cui, Gang
    Cheng, Minlu
    Ding, Li
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Population Pharmacokinetics of the Novel Adenosine A2A Antagonist/Inverse Agonist KW-6356 and Its Active Metabolite Following Single and Multiple Oral Administration in Healthy Individuals and Patients with Parkinson's Disease
    Tayama, Tomonori
    Okada, Hiroki
    Ogawa, Kotoko
    Marsteller, Douglas
    Maeda, Hiroshi
    Hruska, Matthew W.
    Kagawa, Yoshiyuki
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (05): : 549 - 559
  • [9] Development and validation of LC-MS/MS methods for the quantification of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, and its main metabolite M6 in human plasma, urine and feces: Application to a clinical study in healthy Chinese subjects
    Gao, Huaye
    Cheng, Minlu
    Liu, Haijun
    Ding, Li
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2023, 233
1